CLOSE

Specials

  • Genomics Europe
  • March
  • Bioanalytical Services Europe
  • Sustainable Technologies
  • BioTech Startup APAC
  • Life Science Packaging
  • Europe
  • APAC
  • Bioanalytical Services APAC
  • Life Science Compliance
  • Life Science Analytics
  • Bioanalytical Services
  • September
  • June
  • BioTech Startups

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
EUROPE
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Genomics Europe
  • Contributers

Recommended Insights

Using Technology to Increase R&D...

Dr. Jaqui Hodgkinson, VP-Product Development, Pharma...

DNA Infusion-Providing an Identity and...

Judy Murrah, CIO, Applied DNA Sciences Inc

Beyond the Pill, IT Leads the Technology...

Guy Hadari, VP & CIO, Teva Pharmaceuticals

De-risking the Preclinical Phase of...

Ralph Gareus, Director Business Development, The...

Methods and Models from Healthcare Apply...

Dr. Chris Stout, VP - Research & Data Analytics, ATI...

Revolutionizing Genome Editing with CRISPR

Mark Behlke, CSO, Integrated DNA Technologies

The Evolving Internet of Things (IoT) in...

Jerry Power, Executive Director, Institute for...

Aligning IT with the Cadence of your Business

William Leonard, ScD, Chief Information Officer, MPI...

Using Technology to Increase R&D...

Dr. Jaqui Hodgkinson, VP-Product Development, Pharma...

DNA Infusion-Providing an Identity and...

Judy Murrah, CIO, Applied DNA Sciences Inc

Beyond the Pill, IT Leads the Technology...

Guy Hadari, VP & CIO, Teva Pharmaceuticals

De-risking the Preclinical Phase of...

Ralph Gareus, Director Business Development, The...

Methods and Models from Healthcare Apply...

Dr. Chris Stout, VP - Research & Data Analytics, ATI...

Revolutionizing Genome Editing with CRISPR

Mark Behlke, CSO, Integrated DNA Technologies

The Evolving Internet of Things (IoT) in...

Jerry Power, Executive Director, Institute for...

Aligning IT with the Cadence of your Business

William Leonard, ScD, Chief Information Officer, MPI...

Revamping Workflow in Pharma Industry with Technology

By Bozidar Jovicevic, VP, Global Head of Digital Therapeutics, Sanofi [EPA:SAN]
Tweet

With hands-on experience from the field of healthcare with an MD degree from the University of Belgrade, Bozidar Jovicevic has scaled up in his career to be the Vice President, Global Head of Digital Medicines, Sanofi. With a demonstrated history of working in the Healthcare Industry and skilled in Digital Health, Marketing Funnels, Neuro-Linguistic Programming, Product Development & Launch, Bozidar is at the helm of day to day functioning and technical transformation of the company. Recently, he has been an active mentor figure for many young professionals from diverse fields, helping them uplift their work efficiency and output.


Today, the pharma and life sciences industry is embracing the transformative characteristics of technological innovations and introducing massive changes in their entire workflow. By providing innovative ideas for research and development (R&D) of new drugs and handling the confidential patients’ data, technological advancements have become one of the most influential and prominent aspects of the pharma and life sciences industry. As an experienced decision maker, Bozidar Jovicevic, VP of Global Head of Digital Medicines at Sanofi, shares his insight on how technology is the biggest opportunity to be leveraged by the pharma and life sciences industry.


What, in your perspective, are some of the predominant challenges that pharma and life sciences industries face and how can they be addressed?


The pharma industry is riddled with numerous challenges. The unidirectional approach toward the growth of primary care drugs that have kept the industry considerably stable for many years is the first of many challenges. This stability has given rise to the need of staying innovative with time and translating them into pharma drugs. Additionally, the industry is confronted with the challenge of shifting the focus toward specialty drugs and marketing their usage. Taking the aforementioned factors into consideration, the pharma industry needs to leverage technology and the latest scientific discoveries to turn these challenges into opportunities.


How, in your view, can technology aid the pharma industry in tackling these challenges?


Technology has the ability to entirely transform a legacy classical pharma organization into a technologically powered one. It has also shifted the focus of the pharma industry from primary care drugs to highly specialized drugs, which is imminent in today’s time and age. The industry is revamping its complete workflow to accommodate this shift, all the way from the drug R&D and gathering and manipulating patient’s data to simplifying the entire healthcare process for patients.


Technology, as a whole, was first introduced in the pharma industry to improve the backend of the systems and software which the industry employs for various purposes. The need for improvement in CRM systems, logistics service, and supply chain management in the pharma industry has now moved toward improving the core business of the pharma and life sciences industry.


Can you elaborate on how the pharma and life sciences industry is adopting technology to improve their core business?


The core business of the pharma industry is drug R&D and their outcomes. Technology has aided the pharma and life sciences industry in employing genomics and artificial intelligence (AI) for speeding up its drug R&D course. However, the improved drug discovery methods have also brought forth the need to obtain technology for managing data. 


Pharma firms are leveraging technology to derive the results of patient’s health progress after drug consumption so as to further improve the effects of drugs on the patients. Some of these firms are also using data mining to consolidate data from various database platforms so as avail them in coming up with new ideas in drug R&D. Practicing this, the industry has commenced the research on highly specialized and expensive drugs, which are still in oncology stage, and are expected to hit the market in the next few years.


Technology has aided the pharma and life sciences industry in employing genomics and artificial intelligence (AI) for speeding up drug R&D course


Technology also aids pharma firms in reducing the cost of investment in drug R&D. The Distributed Clinical Trial drug development ensures cost reduction in drug R&D as patients need not visit the venue where the clinical trial is being carried out.


How does the pharma industry employ technology to promote and market newly developed specialized drugs?


Earlier, marketing of drugs has chiefly been dependent on doctors meeting sales representatives of the pharma companies; but that is not the case now. Today, more than 50 percent of doctors in the USA do not entertain sales representatives, and when it comes to specialty drugs, the number of doctors following this trend is even higher. Therefore, pharma firms are leveraging online channels to build a good relationship with doctors, thereby, boosting the sales of the newly developed specialized drugs. The pharma companies also need to come up with the concept of designing systems to indulge in multi-channel online platforms to market the newly developed drugs. To do that, companies have to be better at mastering data management and using the right technology that offers them a centralized solution such as cloud for flexibility, customization, and scalability.


Is there an ongoing R&D in the pharma industry that could change how healthcare facilities are offered to patients?


Yes, my team at Sanofi is working on digital medicine or digital therapeutics. Digital medicine brings a complete shift in the paradigm of offering a physical product or a drug to providing a complete healthcare solution. It delivers the patients with the knowledge about the disease they are suffering from, provides them the regular support of nurses and doctors, reminds them to pay a visit to the doctor, and offers digital wearables to monitor bodily functions like heart rate for the complete recovery. It would take around 3 to 4 years of extensive R&D, but the concept would provide patients with full healthcare solution.


What advice would you like to give to decision makers across the pharma organizations?


Data is the most critical/crucial aspect that pharma organizations need to focus on. Everything will eventually move into the cloud but it would benefit the industry only when the operational workflow is shifted from the waterfall model to the agile model. So, CIOs need to be considerate about the introduction of technological innovations for their firms while changing the cultural perspective by shifting from legacy methods to technology-based methods of drug research, development, and marketing. They should also embrace partnerships with technology firms and startups to ensure continuous progress of the industry.


Weekly Brief

loading
> <
  • Life Science Compliance 2021

    Top Vendors

    Current Issue
  • Other 2021

    Top Vendors

    Current Issue

Read Also

The Evolving Internet of Things (IoT) in Healthcare

Jerry Power, Executive Director, Institute for Communications Technology Management, University of Southern California
The Evolving Internet of Things (IoT) in Healthcare

Biopharma Start-Ups and the Development of New Drugs

Ulrich Geilinger, Venture Capitalist, HBM Partners AG
Biopharma Start-Ups and the Development of New Drugs

Future Predictive Analytics Solutions need the Right Level of Regulatory Governance

Frank Wang, System Vice President, IDN Decision Support Analytics, Health First
Future Predictive Analytics Solutions need the Right Level of Regulatory Governance

Using Technology to Increase R&D Productivity in the Life Sciences Sector

Dr. Jaqui Hodgkinson, VP-Product Development, Pharma & Life Sciences, Elsevier R&D Solutions
Using Technology to Increase R&D Productivity in the Life Sciences Sector
De-risking the Preclinical Phase of Immunotherapy Drug Development

De-risking the Preclinical Phase of Immunotherapy Drug Development

Ralph Gareus, Director Business Development, The Jackson Laboratory
Methods and Models from Healthcare Apply to Other Enterprises as Well

Methods and Models from Healthcare Apply to Other Enterprises as Well

Dr. Chris Stout, VP - Research & Data Analytics, ATI Physical Therapy

Revolutionizing Genome Editing with CRISPR

Mark Behlke, CSO, Integrated DNA Technologies
Revolutionizing Genome Editing with CRISPR

The Evolving Financial Crime Regulatory Landscape

Robert WALSH, Deputy CCO, AXA Group
The Evolving Financial Crime Regulatory Landscape
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://genomics-europe.lifesciencesreview.com/cxoinsight/revamping-workflow-in-pharma-industry-with-technology-nwid-313.html